RrhoidCath™by New MedTek Devices
Team · Board · Advisors

The rosterbehind RrhoidCath™.

Built in Sydney. Reviewed by surgeons who have placed the device in theatre. Backed by directors and advisors with decades of medtech, regulatory, and operative track record across Australia, the United States, and the United Kingdom.

New MedTek Devices · Sydney

RrhoidCath Surgical Kit included in Australian Register of Therapeutic Goods (ARTG ID 511628)

RrhoidCath Pump awaiting approval in ARTG

Executive team

Greg Plamondon, Chief Executive Officer of New MedTek Devices
Previously: Saluda Medical · Cochlear (AU + US)
Chief Executive Officer

Greg Plamondon

  • Senior medical device executive with more than 25 years' experience across early-stage ventures and established global organisations.
  • Deep expertise in advancing patient care through both innovation and commercial execution.
  • Proven track record developing and delivering growth strategies that support rapid scale-up and market expansion.
  • Has held senior leadership roles with Saluda Medical and Cochlear, in Australia and the United States.
Val Theisz, Head of Quality and Regulatory at New MedTek Devices
Head of Quality & Regulatory

Val Theisz

  • Regulatory affairs professional with more than 15 years in medical devices, including life-sustaining active implantables.
  • Has held regulatory management positions in both established and start-up companies in Australia.
  • Experience covering the entire product lifecycle, from submissions and pre-market approvals through to ongoing post-market compliance.
  • MEng (Electrical)
  • RAC EU · RAC US (RAPS)
  • CE Marking · FDA 510(k)/PMA · TGA · Health Canada
James Bencke, Head of Product and Operations at New MedTek Devices
Head of Product & Operations

James Bencke

  • More than 15 years in medtech across product delivery, strategy, leadership, operations, and technology innovation, specialising in taking ideas and research through to market.
  • Expertise spanning deep tech, automation, data, and AI applied to the medical industry.
  • An operator and advisor supporting medtech and deep tech commercialisation, with a reputation for tenacity in delivering breakthrough technologies to global markets.
  • BEng · BMedSci · MBA, University of Sydney

Board of Directors

Gary Zamel, Chairman of New MedTek Devices
Chairman

Gary Zamel

  • Serial entrepreneur with 35 years' experience establishing, scaling, and exiting technology and product-led Australian companies; founder and MD of MST Global from 1989 to 2018.
  • Founder and Director of Jellinbah Resources from 1988 to 2002.
  • First seed investor and mentor in Videri Australia from 2014, a new-concept dementia aged-care provider with 28 homes across Sydney.
  • Chairman of IBD Medical, a diabetes product design and distribution company serving international markets for people living with Type 1 and Type 2 diabetes.
  • Chairman of Quantum Lock, a UNSW spin-out in cyber security.
  • BEng, UNSW
  • Hon Fellow, Engineers Australia
  • Fellow, ATSE
Professor David Lubowski AM FRACS, Non-Executive Director
Non-Executive Director

Professor David Lubowski

  • Colorectal surgeon with 30 years of surgical experience, and Conjoint Professor in Surgery at the University of New South Wales.
  • Head of the Department of Colorectal Surgery and Head of the Division of Surgery at St George Hospital, Sydney.
  • Has published more than 120 papers in peer-reviewed national and international journals and 21 textbook chapters, and is colorectal specialty editor of the Australian and New Zealand Journal of Surgery.
  • Foundation Member of the Colorectal Surgical Society of Australia and New Zealand; Fellow of the Royal Society of Medicine, England; and Member of the American Association for the Advancement of Science.
  • AM · FRACS
Leslie Butterfield, Non-Executive Director
Non-Executive Director

Leslie Butterfield

  • Fourteen years as CEO then Regional Managing Director of a listed multinational professional services firm.
  • More than 25 years as a Non-Executive Director and adviser across government; university research; listed, large and small private; and start-up companies.
  • Wide-ranging commercialisation expertise spanning manufacturing, medical, and IT products and services.
  • A project management and management-consulting background, specialising in organisational development, the scale-up of businesses and products, and the use of disruptive technologies to drive growth.
  • BScEng, Rensselaer Polytechnic Institute NY
Dr Bronwyn Evans, Non-Executive Director
Boards: EBR Systems · Building 4.0 CRC · ACOR Consultants
Non-Executive Director

Dr Bronwyn Evans

  • An experienced healthcare executive who has led organisations across industry and governmental bodies, including as Chair of MTAA, Chair of MTPConnect and Director of the Digital Health CRC.
  • Currently Independent Director of EBR Systems (ASX: EBR), Chair of the Building 4.0 CRC and Chair of ACOR Consultants; previously CEO of Engineers Australia and of Standards Australia.
  • Previously Senior Vice President, Clinical & Regulatory at Cochlear Limited (ASX: COH); VP of Finance at the International Standards Organisation (ISO); and Asia Service Manager at GE Healthcare.

Advisory committee

Professor Graham Newstead AM, Colorectal Surgery advisor
AM · Advisor, ASCRS International Committee
Colorectal Surgery

Professor Graham Newstead

  • Colorectal surgeon of more than 45 years, with specialty expertise in proctology, awarded an AM for Australasian and international education, specialty training, and the promotion of health-awareness initiatives.
  • Adjunct Professor at UNSW, Medical Director of Bowel Cancer Australia, and Chairman of the International Council of Coloproctology.
  • Founding Secretary of the Colorectal Surgical Society of Australia and New Zealand (CSSANZ), later its President and then CEO, and founder of the CSSANZ Foundation.
  • Advisor to the International Committee of the American Society of Colon and Rectal Surgeons, and a senior negotiator in federal bowel-health programmes.
  • Holds Fellowships by examination in Surgery from Australasia, the United Kingdom, and the USA, with Honorary Fellowships from the ASCRS, the Royal Society of Medicine, the ACPGBI, the American College of Surgeons, and the Gastroenterological Society of Australia.
  • FRACS · FACS
Dr Steven D Wexner, Colorectal Surgery advisor
1,200+ peer-reviewed manuscripts
Colorectal Surgery

Dr Steven D Wexner

  • Colorectal surgeon with more than 38 years of clinical, academic, and research experience.
  • Physician Executive Director and System Chief of Colorectal Surgery for MedStar Health, and Professor of Surgery at Georgetown University School of Medicine.
  • Previously spent more than three decades at Cleveland Clinic Florida as Chair of Colorectal Surgery and Director of the Ellen Leifer Shulman and Steven Shulman Digestive Disease Center.
  • The first surgeon in North America to popularise the double-stapled ileal pouch anal anastomosis and the colonic J-pouch.
  • Past President of the American Society of Colon and Rectal Surgeons (ASCRS) and the American Board of Colon and Rectal Surgery, and Editor-in-Chief of the journal Surgery.
  • Holds honorary and elected Fellowships from all four Royal Colleges of Surgeons in the United Kingdom and Ireland, alongside dozens of national and international research awards from premier surgical societies.
Professor Peter Farrell, Medtech & Entrepreneurship advisor
Medtech & Entrepreneurship

Professor Peter Farrell

  • A leading medical device executive and entrepreneur, and a member of the United States National Academy of Engineering.
  • Founder and Chair of ResMed Inc, a global leader in sleep-device technology, where he has served in executive and non-executive roles since 1989.
  • Currently Chair of Arcturus Therapeutics (NASDAQ: ARCT), and serves on advisory boards for the Rady Business School and Jacobs Engineering School at UC San Diego, and for WaveGuide.
  • Previous company directorships include NuVasive Inc (NASDAQ: NUVA) and Chair of QRx Pharma.
  • DSc, UNSW
  • BChE Sydney · MS MIT · PhD U.Washington
Dr Joshua Gunn, Diagnostics & Reimbursement advisor
Diagnostics & Reimbursement

Dr Joshua Gunn

  • Chief scientist with more than 15 years in diagnostics, specialising in the development and commercialisation of novel technologies.
  • Adept at navigating coding, coverage, and reimbursement complexities to ensure successful market entry and clinical adoption.
  • Passionate about improving patient outcomes through cost-effective, innovative technologies.
  • Leads multidisciplinary teams and forges partnerships with regulatory bodies, holding new technologies to rigorous clinical and economic standards.

A different way to
recover, starts here.

Contact us